ArticleNeoplasia (New York, N.Y.)2008
Decoy receptor 3 is a prognostic factor in renal cell cancer.
Article in Neoplasia (New York, N.Y.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 67 citations in OpenAlex.
- Migration and invasion of cancer stem cells are prevented by low-intensity pulsed ultrasound therapy.Cancer cell international · 2025Article
- CD15 Is a Risk Predictor and a Novel Target in Clear Cell Renal Cell Carcinoma.Pathobiology : journal of immunopathology, molecular and cellular biology · 2024Article
- Review
- Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma.Translational oncology · 2020Article
- TIPE Regulates DcR3 Expression and Function by Activating the PI3K/AKT Signaling Pathway in CRC.Frontiers in oncology · 2020Article
- Case-Control Study onPharmacogenomics and personalized medicine · 2020Article
- Anti-oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient-derived tumor xenograft model.Head & neck · 2019Article
- The siRNA silencing of DcR3 expression induces Fas ligand-mediated apoptosis in HepG2 cells.Experimental and therapeutic medicine · 2018Article
- Article
- MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.Oncotarget · 2017Article
- A functional polymorphism rs2257440 in the geneInternational journal of clinical and experimental pathology · 2017Article
- Knockdown of Decoy Receptor 3 Impairs Growth and Invasiveness of Hepatocellular Carcinoma Cell Line of HepG2.Chinese medical journal · 2016Article
- Idiopathic pulmonary fibrosis fibroblasts become resistant to Fas ligand-dependent apoptosis via the alteration of decoy receptor 3.The Journal of pathology · 2016Article
- The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker.Oncotarget · 2016Article
- [Novel biomarkers in renal cell carcinoma. Identification and functional characterization].Der Pathologe · 2015Review
- [Cell death in malignant tumors. Relevance of cell death regulation for metastasis].Der Pathologe · 2015Review
- [Structure of biobanks for urological research].Der Urologe. Ausg. A · 2015Review
- Decoy Receptor 3 Improves Survival in Experimental Sepsis by Suppressing the Inflammatory Response and Lymphocyte Apoptosis.PloS one · 2015Article
- Death decoy receptor overexpression and increased malignancy risk in colorectal cancer.World journal of gastroenterology · 2014Article
- The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma.Molecular cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundDecoy receptor 3 (DcR3) is a soluble protein that binds to and inactivates the death ligand CD95L. Here, we studied a possible association between DcR3 expression and prognosis in patients with renal cell carcinomas (RCCs).
methodsA tissue microarray containing RCC tumor tissue samples and corresponding normal tissue samples was generated. Decoy receptor 3 expression in tumors of 560 patients was examined by immunohistochemistry. The effect of DcR3 expression on disease-specific survival and progression-free survival was assessed using univariate analysis and multivariate Cox regression analysis. Decoy receptor 3 serum levels were determined by ELISA.
findingsHigh DcR3 expression was associated with high-grade (P = .005) and high-stage (P = .048) RCCs. The incidence of distant metastasis (P = .03) and lymph node metastasis (P = .002) was significantly higher in the group with high DcR3 expression. Decoy receptor 3 expression correlated negatively with disease-specific survival (P < .001) and progression-free survival (P < .001) in univariate analyses. A multivariate Cox regression analysis retained DcR3 expression as an independent prognostic factor that outperformed the Karnofsky performance status. In patients with high-stage RCCs expressing DcR3, the 2-year survival probability was 25%, whereas in patients with DcR3-negative tumors, the survival probability was 65% (P < .001). Moreover, DcR3 serum levels were significantly higher in patients with high-stage localized disease (P = .007) and metastatic disease (P = .001).
interpretationDcR3 expression is an independent prognostic factor of RCC progression and mortality. Therefore, the assessment of DcR3 expression levels offers valuable prognostic information that could be used to select patients for adjuvant therapy studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.